Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities - A multicenter phase II trial

Lung Cancer

Volumn 49, Issue 1, 2005, Pages 117-123

  Hirsh, Vera ^a   Latreille, Jean ^b   Kreisman, Harvey ^c   Desjardins, Pierre ^b   Ofiara, Linda ^d   Whittom, Renaud ^e   Fox, Susan ^b   Palayew, Mark David ^c   Pintos, Javier ^f  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b HÔPITAL CHARLES LEMOYNE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^f CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Elderly with comorbidities; Metastatic; NSCLC; Phase II study; PS 2 patients; Sequential Vinorelbine Gemcitabine

Indexed keywords

GEMCITABINE; NAVELBINE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FATIGUE; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKOCYTE; LEUKOCYTE DISORDER; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MEDICAL ASSESSMENT; MULTICENTER STUDY; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRAIL ELDERLY; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PALLIATIVE CARE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINBLASTINE;

EID: 20444375856     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.11.029     Document Type: Article

References (25)

1. H. Bulzebruck, R. Bopp, P. Drings, E. Bauer, S. Krysa, and G. Probst New aspects in staging of lung cancer. Prospective validation of the International Union Against Cancer TNM classification Cancer 70 1992 1102 1110
2. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials Br Med J 311 1995 899 909
3. L. Jaakkimainen, P.J. Goodwin, J. Pater, P. Warde, N. Murray, and E. Rapp Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in non-small cell lung cancer J Clin Oncol 8 1990 1301 1309
4. K.S. Albain, J.J. Crowley, M. LeBlanc, and R.B. Livingston Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience J Clin Oncol 9 1991 1618 1626
5. L. Crino, S. Novello, M.R. Migliorino, P. Foggi, C. Gridelli, and L. Galli A phase III randomised trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): impact of PS=2 versus 0 or 1 and age ≥ 70 versus age < 70 on chemotherapy outcome Proc ASCO 21 2002 315a [Abstract #1258]
6. D.H. Johnson, J. Zhu, J. Schiller, C.P. Belani, C. Langer, and J. Krook E1594 - a randomized phase III trial in metastatic non-small cell lung cancer (NSCLC) - outcome of PS 2 patients: an Eastern Cooperative Group trial (ECOG) Proc ASCO 18 1999 461a [Abstract #1779]
7. E. Guadagnoli, A. Weitberg, V. Mor, R.A. Silliman, A.S. Glicksman, and F.J. Cummings The influence of patient age on the diagnosis and treatment of lung and colorectal cancer Arch Intern Med 150 1990 1485 1490
8. V. Mor, S. Masterson-Allen, R.J. Goldberg, F.J. Cummings, A.S. Glicksman, and M.D. Fertwell Relationship between age at diagnosis and treatments received by cancer patients J Am Geriatr Soc 33 1985 585 589
9. C. Gridelli The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study Oncologist 6 Suppl. 1 2001 4 7
10. N. Thatcher, H. Anderson, D.C. Betticher, and M. Ranson Symptomatic benefit from Gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms Anticancer Drugs 6 Suppl. 6 1995 39 48
11. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook Comparison of four chemotherapy regimens for advanced non-small cell lung cancer N Engl J Med 346 2 2002 92 98
12. C.J. Sweeney, J. Zhu, A.B. Sandler, J. Schiller, C.P. Belani, and C. Langer Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase III trial in patients with metastatic non-small cell lung carcinoma Cancer 92 10 2001 2639 2647
13. R.C. Lilenbaum, J. Herndon, M. List, C. Desch, D. Watson, and J. Holland Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (QOL), and cost-effectiveness Proc ASCO 21 2002 [Abstract #2]
14. P.A. Bunn Jr., and K. Kelly New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions Clin Cancer Res 4 1998 1087 1100
15. The Elderly Lung Cancer Vinorelbine Italian Study (ELVIS) Group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer J Natl Cancer Inst 91 1999 66 72
16. K. Kelly The role of single-agent gemcitabine in the treatment of non-small cell lung cancer Ann Oncol 10 Suppl. 5 1999 S53 6
17. H. Anderson, P. Hopwood, R.J. Stephens, N. Thatcher, B. Cottier, and M. Nicholson Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer Br J Cancer 83 2000 447 453
18. W.W. Bokkel Huinik, B. Bergman, A. Chemaissani, W. Dornoff, P. Drings, and P.L. Kellokumpu-Lehtinen Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer Lung Cancer 26 1999 85 94
19. J.F. Vansteenkiste, J.E. Vandebroek, K.I. Nackaerts, P. Weynants, Y.J. Valcke, and D.A. Verresen Clinical benefit response in advanced non-small cell lung cancer: a multicentre prospective randomized phase III study of single agent gemcitabine versus cisplatin-vindesine Ann Oncol 12 2001 1221 1230
20. V. Hirsh, A. Langleben, J. Ayoub, Y. Cormier, J. Pintos, and J.L. Iglesias Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic non small cell lung carcinoma: a phase II multicenter trial Cancer 92 2001 830 835
21. P.J. Hollen, R.J. Gralla, M.G. Kris, C. Cox, C.P. Belani, and S.M. Grunberg Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale Cancer 73 1994 2087 2098
22. P.J. Hesketh, K. Chansky, D.H. Lau, J. Crowley, and D.R. Gandara Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age > 70 or with performance status (PS) 2: a SWOG phase II trial (S0027) Proc ASCO 23 2004 627 [Abstract #7056]
23. A. Depierre, E. Quoix, M. Mercier, J.L. Breton, D. Moro-Sibilot, and D. Debrieuvre Maintenance chemotherapy in advanced non-small cell lung cancer (NSCLC): a randomized study of vinorelbine (V) versus observation (OB) in patients responding to induction therapy. The French Cooperative Oncology Group Proc ASCO 20 2001 [Abstract #1231]
24. M. Krzakowski, M. Wenczl, T. Brodowicz, V. Tzekova, R. Ramlau, and N. Ghilezan Gemcitabine and cisplatin (GC) ± subsequent maintenance therapy with single-agent gemcitabine in advanced non-small cell lung cancer (NSCLC): preliminary results of a randomized trial of the Central European Cooperative Oncology Group (CECOG) Lung Cancer 41 2 2003 S29 [Abstract O-88]
25. C.P. Belani, R.V. Larocca, D.A. Rinaldi, W.J. Tester, P.S. Gable, and M.C. Perry A multicenter, phase III randomized trial for stage IIIB/IV NSCLC of weekly paclitaxel and carboplatin versus standard paclitaxel and carboplatin given every three weeks, followed by weekly paclitaxel Proc ASCO 23 2004 619 [Abstract #7017]